Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06876363Phase 1Recruiting

Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

Role: lead

NCT06605378Recruiting

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

Role: lead

NCT05445128Phase 2Terminated

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Role: lead

NCT04762875Phase 2Terminated

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Role: lead

NCT03932864Phase 1Completed

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Role: lead

NCT04154670Phase 1Completed

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

Role: lead

All 6 trials loaded